[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07603518":3,"trial-entities:NCT07603518":112,"trial-summary:NCT07603518":116},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":25,"primary_purpose":26,"phases":27,"enrollment_info":29,"interventions":32,"primary_outcomes":43,"secondary_outcomes":48,"sex":59,"minimum_age":60,"maximum_age":61,"healthy_volunteers":62,"eligibility_criteria":63,"std_ages":82,"locations":84,"central_contacts":98,"overall_officials":107,"references":110,"see_also_links":111},"NCT07603518","IRB00542166","The Pharmacokinetics of a Hemp-Based Topical Product","The Pharmacokinetics of a Hemp-Based Topical Cannabinoid Product in a Sanitized and Controlled Environment","RECRUITING","2027-09-01","2026-09","2026-09-03","2026-05-26","Johns Hopkins University","OTHER",false,"This study will evaluate the pharmacokinetic effects of acute and chronic dosing of a hemp-based cannabidiol (CBD) topical lotion with low levels of delta-9-tetrahydrocannabinol (THC) in a sanitized and controlled environment.","Participants (N = 6) will complete an 7-day residential study using a high CBD\u002Flow D9-THC lotion. The lotion is applied to the participants' upper arms four times daily in a sanitized and controlled procedure that eliminates the potential for specimen contamination. Oral fluid (OF) is collected before and after application (six samples\u002Fday); blood and urine are collected once\u002Fday. On discharge day, participants provide an intentionally contaminated OF sample. Participants return after a 7-day washout to provide 4 additional OF specimens, one \"clean\" and three more intentionally contaminated samples over a two-hour course.",[19],"Cannabis",[21,22,23,24],"Cannabinoids","Pharmacology","Contamination","Hemp lotion","INTERVENTIONAL","BASIC_SCIENCE",[28],"PHASE1",{"count":30,"type":31},20,"ESTIMATED",[33,39],{"type":34,"name":35,"description":36,"armGroupLabels":37},"DRUG","CBD","CBD will be topically applied",[38],"Topical CBD Product with low level of THC",{"type":34,"name":40,"description":41,"armGroupLabels":42},"THC","THC will be topically applied",[38],[44],{"measure":45,"description":46,"timeFrame":47},"Change in concentration of oral fluid cannabinoids","Concentration of cannabinoids will be measured in oral fluid (unit of measurement: nanograms\u002FmL)","Days 1-7 and Day 14",[49,52,55],{"measure":50,"description":51,"timeFrame":47},"Change in concentration of blood cannabinoids","Concentration of cannabinoids will be measured in blood (unit of measurement: nanograms\u002FmL)",{"measure":53,"description":54,"timeFrame":47},"Change concentration of urine cannabinoids","Concentration of cannabinoids will be measured in urine (unit of measurement: nanograms\u002FmL)",{"measure":56,"description":57,"timeFrame":58},"Change in the number of total minutes of sleep","Change in sleep patterns. Change in the number of total minutes of sleep will be measured via vital monitoring and sleep profiling","Days 1-7","ALL","18 Years","55 Years",true,{"inclusion":64,"exclusion":74,"raw_text":81},[65,66,67,68,69,70,71,72,73],"Have provided written informed consent","Be between the ages of 18 and 55","Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests","Test negative for recent cannabis use in urine at the screening visit and again upon admission for the inpatient stay.","Test negative for other drugs of abuse, including alcohol, at the screening visit and again upon admission for the inpatient stay.","Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at each study visit.","Have a body mass index (BMI) in the range of 18 to 38 kg\u002Fm2","Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg","Report prior experience using cannabis or CBD products.",[75,76,77,78,79,80],"Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine in the month prior to the screening visit.","History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.","Current use of medications which, in the opinion of the investigator or medical monitor, will interfere with the study results or the safety of the subject.","History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples.","Known allergy to any ingredients in the study drug.","Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing.","Inclusion Criteria:\n\n* Have provided written informed consent\n* Be between the ages of 18 and 55\n* Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests\n* Test negative for recent cannabis use in urine at the screening visit and again upon admission for the inpatient stay.\n* Test negative for other drugs of abuse, including alcohol, at the screening visit and again upon admission for the inpatient stay.\n* Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at each study visit.\n* Have a body mass index (BMI) in the range of 18 to 38 kg\u002Fm2\n* Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg\n* Report prior experience using cannabis or CBD products.\n\nExclusion Criteria:\n\n* Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine in the month prior to the screening visit.\n* History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.\n* Current use of medications which, in the opinion of the investigator or medical monitor, will interfere with the study results or the safety of the subject.\n* History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples.\n* Known allergy to any ingredients in the study drug.\n* Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing.",[83],"ADULT",[85],{"facility":86,"status":8,"city":87,"state":88,"zip":89,"country":90,"contacts":91,"geoPoint":95},"Behavioral Pharmacology Research Unit","Baltimore","Maryland","21224","United States",[92],{"name":93,"role":94},"Tory Spindle, Ph.D.","PRINCIPAL_INVESTIGATOR",{"lat":96,"lon":97},39.29038,-76.61219,[99,104],{"name":100,"role":101,"phone":102,"email":103},"Lizzie Wilkerson","CONTACT","4105500529","lizziewilkerson307@gmail.com",{"name":105,"role":101,"email":106},"Tory Spindle","tspindle@jhmi.edu",[108],{"name":109,"affiliation":13,"role":94},"Tory Spindle, PhD",[],[],{"nct_id":4,"conditions":113,"biomarkers":115},[114],"Healthy Volunteers",[],{"nct_id":4,"found":62,"summary":117,"prompt_version":127},{"design":118,"status":119,"heading":120,"summary":121,"follow_up":122,"word_count":123,"commitments":124,"compensation":125,"drugs_mentioned":126},"This is an interventional study with 6 participants. It is not specified if it is randomized or blinded.","completed","Understanding Topical CBD and THC Absorption","This study is looking at how your body absorbs cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) when applied to the skin in a hemp-based lotion. Researchers want to see how much of these substances get into your system after using the lotion once and over several days. They will measure the levels of CBD and THC in your oral fluid (spit) to understand this. You might be able to join if you are between 18 and 55 years old, in good health, and have not recently used cannabis. The study aims to understand how these topical products are processed by the body. The current recruitment status is unclear.","You will return after a 7-day washout period to provide additional oral fluid samples.",106,"You would participate in a 7-day residential stay where the lotion is applied four times daily. Oral fluid, blood, and urine samples will be collected, and you will return after a 7-day break for more oral fluid collections.","Not stated in the trial record.",[35,40],"v2"]